<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:56:31Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5988804" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5988804</identifier>
        <datestamp>2019-07-03</datestamp>
        <setSpec>brjcancer</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Cancer</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-0920</issn>
              <issn pub-type="epub">1532-1827</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5988804</article-id>
              <article-id pub-id-type="pmcid">PMC5988804</article-id>
              <article-id pub-id-type="pmc-uid">5988804</article-id>
              <article-id pub-id-type="pmid">29765151</article-id>
              <article-id pub-id-type="pmid">29765151</article-id>
              <article-id pub-id-type="publisher-id">87</article-id>
              <article-id pub-id-type="doi">10.1038/s41416-018-0087-9</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Apatorsen plus docetaxel versus docetaxel alone in
platinum-resistant metastatic urothelial carcinoma (Borealis-2)</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosenberg</surname>
                    <given-names>Jonathan E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hahn</surname>
                    <given-names>Noah M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Regan</surname>
                    <given-names>Meredith M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Werner</surname>
                    <given-names>Lillian</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alva</surname>
                    <given-names>Ajjai</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>George</surname>
                    <given-names>Saby</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Picus</surname>
                    <given-names>Joel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alter</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Balar</surname>
                    <given-names>Arjun</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoffman-Censits</surname>
                    <given-names>Jean</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Grivas</surname>
                    <given-names>Petros</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lauer</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guancial</surname>
                    <given-names>Elizabeth A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoimes</surname>
                    <given-names>Christopher</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sonpavde</surname>
                    <given-names>Guru</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Albany</surname>
                    <given-names>Constantine</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stein</surname>
                    <given-names>Mark N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff16">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Breen</surname>
                    <given-names>Tim</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff17">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jacobs</surname>
                    <given-names>Cindy</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Anderson</surname>
                    <given-names>Kirsten</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bellmunt</surname>
                    <given-names>Joaquim</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lalani</surname>
                    <given-names>Aly-Khan A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pal</surname>
                    <given-names>Sumanta</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff19">19</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9201-3217</contrib-id>
                  <name>
                    <surname>Choueiri</surname>
                    <given-names>Toni K.</given-names>
                  </name>
                  <address>
                    <phone>+(617) 632-5456</phone>
                    <email>Toni_Choueiri@DFCI.HARVARD.EDU</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Sidney Kimmel Comprehensive Cancer Center, </institution><institution>Johns Hopkins University, </institution></institution-wrap>Baltimore, MD USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, MA USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9081 2336</institution-id><institution-id institution-id-type="GRID">grid.412590.b</institution-id><institution>University of Michigan Comprehensive Cancer Center, </institution></institution-wrap>Ann Arbor, MI USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2181 8635</institution-id><institution-id institution-id-type="GRID">grid.240614.5</institution-id><institution>Roswell Park Cancer Institute, </institution></institution-wrap>Buffalo, NY USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution>Siteman Cancer Center, </institution><institution>Washington University, </institution></institution-wrap>St. Louis, MO USA </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 6328</institution-id><institution-id institution-id-type="GRID">grid.239835.6</institution-id><institution>John Theurer Cancer Center, </institution><institution>Hackensack University Medical Center, </institution></institution-wrap>Hackensack, NJ USA </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>New York University Perlmutter Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0442 8581</institution-id><institution-id institution-id-type="GRID">grid.412726.4</institution-id><institution>Sidney Kimmel Cancer Center at Jefferson, </institution></institution-wrap>Philadelphia, PA USA </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution>Cleveland Clinic Taussig Cancer Institute, </institution></institution-wrap>Cleveland, OH USA </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2188 8502</institution-id><institution-id institution-id-type="GRID">grid.266832.b</institution-id><institution>University of New Mexico Cancer Center, </institution></institution-wrap>Albuquerque, NM USA </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9174</institution-id><institution-id institution-id-type="GRID">grid.16416.34</institution-id><institution>University of Rochester Wilmot Cancer Institute, </institution></institution-wrap>Rochester, NY USA </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0418 9795</institution-id><institution-id institution-id-type="GRID">grid.473817.e</institution-id><institution>University Hospitals Seidman Cancer Center, </institution></institution-wrap>Cleveland, OH USA </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000000106344187</institution-id><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution>University of Alabama Comprehensive Cancer Center, </institution></institution-wrap>Birmingham, AL USA </aff>
                <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2287 3919</institution-id><institution-id institution-id-type="GRID">grid.257413.6</institution-id><institution>Indiana University Melvin and Bren Simon Cancer Center, </institution></institution-wrap>Indianapolis, IN USA </aff>
                <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8796</institution-id><institution-id institution-id-type="GRID">grid.430387.b</institution-id><institution>Rutgers Cancer Institute of New Jersey, </institution></institution-wrap>New Brunswick, NJ USA </aff>
                <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.428706.f</institution-id><institution>Hoosier Cancer Research Network, </institution></institution-wrap>Indianapolis, IN USA </aff>
                <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0411 1103</institution-id><institution-id institution-id-type="GRID">grid.476616.4</institution-id><institution>OncoGenex Pharmaceuticals, Inc., </institution></institution-wrap>Bothell, WA USA </aff>
                <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0421 8357</institution-id><institution-id institution-id-type="GRID">grid.410425.6</institution-id><institution>City of Hope Comprehensive Cancer Center, </institution></institution-wrap>Duarte, CA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>5</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>29</day>
                <month>5</month>
                <year>2018</year>
              </pub-date>
              <volume>118</volume>
              <issue>11</issue>
              <fpage>1434</fpage>
              <lpage>1441</lpage>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>10</month>
                  <year>2017</year>
                </date>
                <date date-type="rev-recd">
                  <day>23</day>
                  <month>3</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>28</day>
                  <month>3</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Cancer Research UK 2018</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Note:</bold> This work is published under the
standard license to publish agreement. After 12 months the work will become freely
available and the license terms will switch to a Creative Commons Attribution 4.0
International licence (CC BY 4.0).</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">A randomised study to assess the addition of apatorsen, an antisense
oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with
metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based
chemotherapy.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Multicentre, phase II study with 1:1 randomisation to apatorsen
(three loading doses at 600 mg intravenous followed by weekly doses) plus
docetaxel (75 mg/m<sup>2</sup> intravenous every 21 days) (A/D) or
docetaxel alone. Overall survival (OS) was the primary end point with a <italic>P</italic> value &lt;0.1 (one-sided) being positive.
Progression-free survival (PFS), objective response rate (ORR), safety, and effect
of Hsp27 levels on outcomes were secondary end points.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Patients randomised to A/D (<italic>n</italic> = 99) had improved OS compared to docetaxel alone (<italic>n</italic> = 101): HR: 0.80, 80% CI: 0.65–0.98, <italic>P</italic> = 0.0784, median 6.4 vs 5.9 months. PFS and ORR were
similar in both arms. A/D had more incidence of sepsis and urinary tract
infections. Patients with baseline Hsp27 levels &lt;5.7 ng/mL had improved OS
compared to those with levels ≥5.7 ng/mL. Patients with a decline or ≤20.5%
increase in Hsp27 from baseline benefited more from A/D than those with &gt;20.5%
increase.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">A/D met its predefined OS end point in patients with
platinum-refractory mUC in this phase II trial. This trial is hypothesis
generating requiring further study before informing practice.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Bladder cancer</kwd>
                <kwd>Prognostic markers</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Cancer Research UK 2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par5">Heat shock proteins (Hsp) are a family of highly conserved proteins
whose expression is induced by cell stressors such as hyperthermia, oxidative
stress, cytotoxic chemotherapy, and radiation.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Hsp27 is highly expressed in many
cancers and is associated with poor prognosis.<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup> Hsp27 also stabilises mutated or inappropriately
activated oncoproteins that contribute to the initiation, growth, and metastasis of
human cancers.<sup><xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR7">7</xref></sup> While Hsp27 is expressed in low levels in normal
bladder epithelium,<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> expression is increased in bladder
cancer.<sup><xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref></sup></p>
              <p id="Par6">Apatorsen (OGX-427) is an antisense oligonucleotide (ASO) designed to
bind to Hsp27 mRNA, resulting in the inhibition of the production of Hsp27
protein.<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>
Apatorsen is similar to endogenous DNA but contains second-generation ASO chemical
modifications intended to optimise its pharmacological potency, pharmacokinetics,
and safety profile. In vitro and in vivo evidence indicates that Hsp27 inhibition
leads to inhibition of tumour growth and sensitisation to cytotoxic
chemotherapy,<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>
and a trial of apatorsen as intravesical therapy for non-muscle invasive bladder
cancer showed promising anticancer activity.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> Phase I studies of apatorsen as
a single agent and in combination with docetaxel appeared to be well tolerated even
at the highest dose of 1000 mg.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup></p>
              <p id="Par7">We report the efficacy and safety of apatorsen in combination with
docetaxel compared to docetaxel alone in patients with metastatic urothelial
carcinoma previously treated with platinum-based chemotherapy. This randomised,
controlled phase II trial with a primary end point of overall survival was designed
to provide a strong rationale for whether to move forward with a phase III trial in
this patient population.</p>
            </sec>
            <sec id="Sec2">
              <title>Patients and methods</title>
              <sec id="Sec3">
                <title>Study design and participants</title>
                <p id="Par8">This was a randomised, phase II, investigator-sponsored,
multicentre, open-label trial conducted among academic and community sites within
the Hoosier Cancer Research Network (HCRN). Patients with metastatic or locally
advanced inoperable urothelial carcinoma (TNM staging T4b, N2, N3, or M1)
previously treated with platinum-based chemotherapy were enrolled. To be eligible,
patients 18 years or older were required to have measurable disease, an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 or 1, and estimated life
expectancy of 3 or more months. All patients must have received at least one prior
platinum-based chemotherapy regimen with a maximum of two regimens. Patients who
relapsed within 1 year of platinum-based perioperative chemotherapy were eligible.
Patients whose tumours contained variant histological features were eligible if
the tumour was not considered a pure histologic variant; however, patients with
any amount of small cell carcinoma were not eligible. Patients were required to
have adequate organ function (serum creatinine ≤1.5× upper limit of normal (ULN)),
no worse than grade 1 peripheral neuropathy, no known brain or spinal cord
metastases, no active second malignancy, no cerebrovascular accident, myocardial
infarction, or pulmonary embolus within 3 months of enrollment, and no prior
treatment with docetaxel.</p>
              </sec>
              <sec id="Sec4">
                <title>Randomisation</title>
                <p id="Par9">Patients were randomly assigned to apatorsen plus docetaxel or
docetaxel alone in a one-to-one ratio using permuted blocks within strata.
Randomisation was generated using a clinical trial management system software
(OnCore) and patients were stratified based on 0 vs 1–3 adverse Bellmunt
prognostic factors (liver metastases, haemoglobin &lt;10 g/dL, ECOG performance
status 1) and time from prior systemic chemotherapy (&lt;3 months vs ≥3
months).<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup></p>
              </sec>
              <sec id="Sec5">
                <title>Procedures</title>
                <p id="Par10">For patients assigned apatorsen plus docetaxel, apatorsen 600 mg
was administered intravenously in three separate loading doses separated by at
least one non-treatment day over a 9-day period. Patients were administered an
antihistamine or an H2 antagonist prior to each of the three loading doses.
Following the loading doses, patients received docetaxel
75 mg/m<sup>2</sup> in 21-day cycles and apatorsen 600 mg weekly
until disease progression, unacceptable toxicity, or a maximum of 10 cycles of
docetaxel. Patients who completed 10 cycles or stopped docetaxel for toxicity
continued maintenance apatorsen until disease progression or unacceptable toxicity
related to apatorsen. For patients assigned docetaxel alone, docetaxel was
administered at a dose of 75 mg/m<sup>2</sup> every 21 days until
disease progression, unacceptable toxicity, or a maximum of 10 cycles of
docetaxel. Dose reductions for docetaxel (from 75 mg/m<sup>2</sup>
to 60 mg/m<sup>2</sup> to 45 mg/m<sup>2</sup>)
were required for haematologic toxicity, peripheral sensory neuropathy, or
mucositis. Dose reductions for apatorsen (from 600 mg to 500 mg to 400 mg) were
required for renal toxicity, and dose reductions for both agents were required for
hepatotoxicity.</p>
              </sec>
              <sec id="Sec6">
                <title>Study end points</title>
                <p id="Par11">The primary end point was overall survival (OS), defined from
randomisation until death due to any cause, or censored on date last known alive.
Secondary efficacy end points were progression-free survival (PFS), defined from
randomisation to objective disease progression or death from any cause, whichever
occurred first, or censored at date of last disease evaluation without
progression; objective response rate (ORR; complete or partial response as best
overall response) and duration of response, which were evaluated by RECIST
criteria version 1.1. Radiographic evaluations were performed at baseline with
cross-sectional imaging and repeated every 6 weeks until disease progression.
Patients with bone metastases on baseline bone scan were required to have imaging
every 6 weeks for the first 4 cycles and then every 12 weeks thereafter until
disease progression. If any new clinical signs or symptoms of disease progression
developed, imaging was repeated as clinically indicated. Safety was reported
according to National Cancer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE version 4.0) and assessed from initiation of study treatment
until 30 days after last study therapy. Exploratory objectives included assessing
the associations of baseline and post-treatment serum Hsp27 levels with survival
outcomes. Hsp27 levels were analysed by a central laboratory using enzyme-linked
immunosorbent assay analysis, as has been previously
described.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup></p>
              </sec>
              <sec id="Sec7">
                <title>Statistical analysis</title>
                <p id="Par12">This phase II study was designed to have 90% power with one-sided
0.10 significance level to detect a 33% reduction in the OS hazard rate with
docetaxel and apatorsen compared with docetaxel alone [hazard ratio (docetaxel and
apatorsen/docetaxel) = 0.667], assuming an exponential distribution of OS, and
median OS of 6 months on docetaxel alone.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> The specified phase II error
levels were considered to provide adequate precision of the hazard ratios (HR) in
order to inform the design of a subsequent phase III trial. The randomised,
controlled design specified one interim analysis for futility after ~81 deaths and
final analysis after 162 deaths. The cutoff date for final analysis was 10 October
2016.</p>
                <p id="Par13">Patient and clinical characteristics were summarised as numbers and
percentage for categorical variables and median with range for continuous
variables. OS and PFS were compared between the two treatment assignments using a
stratified log-rank test with a one-sided <italic>α</italic> = 0.10. The Kaplan–Meier (KM) method was used to estimate OS and PFS
distributions by treatment arm. Stratified Cox proportional hazards (PH) models
estimated hazard ratios (HR) and 80% two-sided confidence intervals, which
corresponds to one-sided <italic>α</italic> = 0.10, in
unadjusted and multivariable models. Subgroup analyses investigated treatment
effects according to the stratification factors, estimating HRs and testing for
treatment-by-subgroup interaction in Cox PH models.</p>
                <p id="Par14">ORR was summarised as numbers and percentage of participants by
treatment assignments with two-sided 80% CI and compared using Fisher’s exact
tests. Median duration of response was estimated using KM method in patients who
achieved partial or complete response as best overall response, defined from time
objective response was first observed until disease progression or death. A
planned stratified Cox PH model assessed the association of baseline serum Hsp27
level with OS and to test the treatment-by-Hsp27 interaction. Baseline serum Hsp27
levels were categorized at the median for assessing the associations with OS,
given that no clinically meaningful cutoff point had been previously established.
Among patients who were alive after cycle 2, the association of percentage change
of Hsp27 level from baseline to end of cycle 2 with OS (re-defined from end of
cycle 2 as landmark analysis) was investigated similarly.</p>
              </sec>
            </sec>
            <sec id="Sec8" sec-type="results">
              <title>Results</title>
              <sec id="Sec9">
                <title>Patients</title>
                <p id="Par15">Between August 2013 and September 2015, 200 patients were enrolled
at 32 study sites in the United States. Ninety-nine patients were randomised to
docetaxel and apatorsen and 101 patients to treatment with docetaxel alone.
Overall, 194 participants had complete follow-up for survival and 6 were lost to
follow-up or withdrew consent without survival follow-up. All 200 participants
were included in the intention-to-treat (ITT) analysis population
(Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Baseline characteristics were
well balanced as shown in Table <xref rid="Tab1" ref-type="table">1</xref>.
Overall, median age of participants was 67 years (interquartile range, IQR 59–74)
and 149 participants (74.5%) were male. Eighty-four (42.0%) had ECOG performance
status of 0 at screening. In terms of patient stratification, 140 (70%) had 1–3
Bellmunt prognostic factors and 87 (43.5%) had time from prior systemic
chemotherapy &lt;3 months.<fig id="Fig1"><label>Fig. 1</label><caption><p>Trial CONSORT flow diagram</p></caption><graphic xlink:href="41416_2018_87_Fig1_HTML" id="d32e797"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Treatment assignment</th></tr><tr><th>Characteristic, <italic>n</italic>
(%)</th><th>Apatorsen and docetaxel<break/> (<italic>n</italic> = 99)</th><th>Docetaxel (<italic>n</italic> = 101)</th></tr></thead><tbody><tr><td>Age, median years (range)</td><td>68 (43–90)</td><td>67 (35–92)</td></tr><tr><td colspan="3">Sex</td></tr><tr><td>  Male</td><td>74 (74.7%)</td><td>75 (74.3%)</td></tr><tr><td>  Female</td><td>25 (25.3%)</td><td>26 (25.6%)</td></tr><tr><td colspan="3">Race</td></tr><tr><td>  Caucasian</td><td>89 (89.9%)</td><td>92 (91.1%)</td></tr><tr><td>  African American</td><td>3 (3%)</td><td>4 (4%)</td></tr><tr><td>  Asian</td><td>5 (5.1%)</td><td>3 (3%)</td></tr><tr><td>  Unknown</td><td>2 (2%)</td><td>2 (2%)</td></tr><tr><td colspan="3">ECOG performance
status<sup>a</sup></td></tr><tr><td>  0</td><td>43 (43.4%)</td><td>41 (40.6%)</td></tr><tr><td>  1</td><td>56 (56.6%)</td><td>59 (58.4%)</td></tr><tr><td colspan="3">Urothelial carcinoma (at study entry)</td></tr><tr><td>  Metastatic</td><td>85 (85.9%)</td><td>87 (86.1%)</td></tr><tr><td>  Locally advanced</td><td>6 (6.1%)</td><td>10 (9.9%)</td></tr><tr><td>  Unknown</td><td>8 (8.1%)</td><td>4 (4%)</td></tr><tr><td colspan="3">Primary surgery</td></tr><tr><td>  Yes</td><td>40 (40.4%)</td><td>36 (35.6%)</td></tr><tr><td colspan="3">Prior cisplatin use</td></tr><tr><td>  Yes</td><td>70 (70.7%)</td><td>72 (71.3%)</td></tr><tr><td colspan="3">Prior carboplatin use</td></tr><tr><td>  Yes</td><td>38 (38.4%)</td><td>41 (40.6%)</td></tr><tr><td colspan="3">Primary disease site(s)</td></tr><tr><td>  Bladder</td><td>64 (64.6%)</td><td>72 (71.3%)</td></tr><tr><td>  Renal pelvis</td><td>27 (27.3%)</td><td>13 (12.9%)</td></tr><tr><td>  Ureter</td><td>13 (13.1%)</td><td>14 (13.9%)</td></tr><tr><td>  Urethra</td><td>7 (7.1%)</td><td>9 (8.9%)</td></tr><tr><td colspan="3">Metastatic sites</td></tr><tr><td>  Liver</td><td>28 (28.3%)</td><td>25 (24.8%)</td></tr><tr><td>  Lung</td><td>34 (34.3%)</td><td>35 (34.7%)</td></tr><tr><td>  Bone</td><td>19 (19.2%)</td><td>21 (20.8%)</td></tr><tr><td>  Lymph nodes</td><td>56 (56.6%)</td><td>52 (51.5%)</td></tr><tr><td colspan="3">Bellmunt prognostic
factors<sup>b</sup></td></tr><tr><td>  0</td><td>27 (27.3%)</td><td>32 (31.7%)</td></tr><tr><td>  1</td><td>42 (42.4%)</td><td>35 (34.7%)</td></tr><tr><td>  2</td><td>23 (23.2%)</td><td>26 (25.7%)</td></tr><tr><td>  3</td><td>7 (7.1%)</td><td>7 (6.9%)</td></tr></tbody></table><table-wrap-foot><p>Prior paclitaxel use was balanced between both arms (<italic>n</italic> = 10 arm A and <italic>n</italic> = 12 arm B).</p><p><italic>ECOG</italic> Eastern Cooperative
Oncology Group.</p><p><sup>a</sup>One patient in the docetaxel arm had
ECOG performance status of 2.</p><p><sup>b</sup>One patient in the docetaxel arm had
unknown Bellmunt prognostic factors</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec10">
                <title>Therapy administration</title>
                <p id="Par16">Among patients who started docetaxel, a median of two cycles were
received in both groups and among those who received apatorsen, a median of 6
weeks (or doses) of treatment were received. Seven patients went on to receive
maintenance apatorsen after stopping docetaxel, with additional weeks of apatorsen
reported as: 1, 2, 3, 7, 7, 33, and 61 weeks for these patients.</p>
              </sec>
              <sec id="Sec11">
                <title>Primary end point: overall survival</title>
                <p id="Par17">Median follow-up time for all surviving patients was 21.6 months
(range, &lt;1–35.3 months). At the time of analysis, 163 deaths were reported,
with 77 (77.8%) assigned docetaxel and apatorsen and 86 (85.1%) assigned
docetaxel. Patients assigned to docetaxel and apatorsen had a reduction in hazard
of death as compared to patients assigned docetaxel alone (HR: 0.80; 80% CI:
0.65–0.98, one-sided <italic>P</italic> = 0.0784, median OS 6.4
vs 5.9 months). The estimated 12-month OS was 34.4% and 25.0% among patients
assigned to docetaxel and apatorsen vs docetaxel alone, respectively
(Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan–Meier estimate of overall survival (OS). A apatorsen, D
docetaxel, HR hazard ratio, CI confidence interval</p></caption><graphic xlink:href="41416_2018_87_Fig2_HTML" id="d32e1199"/></fig></p>
              </sec>
              <sec id="Sec12">
                <title>Secondary end points and subgroup analysis</title>
                <p id="Par18">Patients assigned to docetaxel and apatorsen had a reduced hazard
of disease progression or death as compared to patients assigned to docetaxel
alone, although the results were not statistically significant (HR: 0.80, 80% CI:
0.64–1.01, one-sided <italic>P</italic> = 0.1069, median PFS 1.8
vs 1.6 months, estimated 12-month PFS 8.7% vs 3.8%).</p>
                <p id="Par19">One-hundred and forty-five patients had evaluable disease by RECIST
1.1 criteria. The ORR was 16.1% (80% CI: 11.5–21.9) for patients assigned
docetaxel and apatorsen vs 10.9% (80% CI: 7.1–16.0) for those assigned docetaxel
alone (one-sided <italic>P</italic> = 0.1531). Median duration
of response was 6.2 months and 4.4 months in the docetaxel plus apatorsen and
docetaxel alone responders, respectively.</p>
                <p id="Par20">Subgroup analysis was performed on patients with Bellmunt
prognostic factors 0 vs 1–3 as well as those with time from prior systemic
chemotherapy &lt;3 vs ≥3 months. In participants with 0 risk factors, treatment
with docetaxel and apatorsen vs docetaxel alone resulted in a median OS 14.3 vs
10.9 months (HR: 0.91, 80% CI: 0.59–1.42), compared to a median OS of 5.6 vs 5.1
months in those with 1–3 risk factors (HR: 0.77, 80% CI: 0.61–0.97). In
participants with time from prior systemic chemotherapy ≥3 months, median OS was
8.0 vs 6.7 months for patients assigned docetaxel and apatorsen vs docetaxel alone
(HR: 0.89, 80% CI: 0.67–1.18) and in those with time from prior systemic
chemotherapy &lt;3 months, the median OS was 5.9 vs 4.7 months (HR: 0.71, 80% CI:
0.53–0.96) for patients assigned docetaxel and apatorsen vs docetaxel,
respectively.</p>
                <p id="Par21">There was also no significant impact on survival for patients
having primary surgery, compared to those that did not (HR: 0.90; 80% CI:
0.73–1.12, one-sided <italic>P</italic> = 0.2638).</p>
              </sec>
              <sec id="Sec13">
                <title>Safety</title>
                <p id="Par22">Of the 200 participants randomised, 189 (93 assigned docetaxel plus
apatorsen and 96 assigned docetaxel alone) initiated protocol treatment and were
included in the safety population. Overall, 187 (98.9%) patients experienced an
adverse event (AE) of any grade. The most common all-grade AEs were fatigue,
anorexia, constipation, diarrhoea, nausea, anaemia, leukopaenia, and neutropaenia
(Table <xref rid="Tab2" ref-type="table">2</xref>). Among patients assigned to
docetaxel and apatorsen, 77 (82.8%) had at least one grade 3–5 AE reported
compared with 72 (75.0%) patients assigned to docetaxel alone. Common grade 3–5
AEs, including neutropaenia, leukopaenia, anaemia, and febrile neutropaenia, were
well balanced between both groups. Patients treated with docetaxel and apatorsen
had greater incidence of sepsis (15.1% vs 8.3%; <italic>n</italic> = 14 vs 8) and urinary tract infections (14% vs 7.3%; <italic>n</italic> = 13 vs 7) compared to those treated with docetaxel
alone. Thirteen percent of patients discontinued treatment due to unacceptable
adverse events (16.2% (<italic>n</italic> = 16) assigned
docetaxel and apatorsen and 9.9% (<italic>n</italic> = 10)
assigned docetaxel). Five patients in each arm experienced grade 5 AEs. In the
docetaxel and apatorsen arm, one was possibly drug related to the treatment
combination, and one was possibly drug related to apatorsen only. One death in
each arm was possibly drug related to docetaxel alone.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Selected adverse events among the safety population initiating
assigned treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9">Treatment assignment</th></tr><tr><th/><th colspan="4">Patients given docetaxel and apatorsen (<italic>n</italic> = 93)</th><th colspan="4">Patients given docetaxel (<italic>n</italic> = 96)</th></tr><tr><th/><th>Grades 1–2</th><th>Grade 3</th><th>Grade 4</th><th>Grade 5</th><th>Grades 1–2</th><th>Grade 3</th><th>Grade 4</th><th>Grade 5</th></tr></thead><tbody><tr><td>Fatigue</td><td>56 (60%)</td><td>7 (7%)</td><td>0</td><td>0</td><td>54 (56%)</td><td>12 (12%)</td><td>0</td><td>0</td></tr><tr><td>Diarrhoea</td><td>40 (43%)</td><td>7 (7%)</td><td>0</td><td>0</td><td>30 (31%)</td><td>5 (5%)</td><td>0</td><td>0</td></tr><tr><td>Anaemia</td><td>24 (26%)</td><td>16 (17%)</td><td>0</td><td>0</td><td>25 (26%)</td><td>10 (10%)</td><td>2 (2%)</td><td>0</td></tr><tr><td>Nausea</td><td>39 (42%)</td><td>2 (2%)</td><td>0</td><td>0</td><td>31 (32%)</td><td>3 (3%)</td><td>0</td><td>0</td></tr><tr><td>Anorexia</td><td>42 (45%)</td><td>0</td><td>0</td><td>0</td><td>29 (30%)</td><td>1 (1%)</td><td>0</td><td>0</td></tr><tr><td>Neutropaenia</td><td>4 (4%)</td><td>14 (15%)</td><td>19 (20%)</td><td>0</td><td>4 (4%)</td><td>11 (11%)</td><td>18 (19%)</td><td>0</td></tr><tr><td>Constipation</td><td>35 (38%)</td><td>2 (2%)</td><td>0</td><td>0</td><td>24 (25%)</td><td>1 (1%)</td><td>0</td><td>0</td></tr><tr><td>Dyspnea</td><td>22 (24%)</td><td>6 (6%)</td><td>0</td><td>0</td><td>26 (27%)</td><td>3 (3%)</td><td>1 (1%)</td><td>0</td></tr><tr><td>Leukopaenia</td><td>4 (4%)</td><td>18 (19%)</td><td>9 (10%)</td><td>0</td><td>4 (4%)</td><td>14 (14%)</td><td>5 (5%)</td><td>0</td></tr><tr><td>Alopecia</td><td>26 (28%)</td><td>0</td><td>0</td><td>0</td><td>26 (27%)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Peripheral neuropathy</td><td>27 (29%)</td><td>1 (1%)</td><td>0</td><td>0</td><td>22 (23%)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Creatinine increased</td><td>28 (30%)</td><td>2 (2%)</td><td>0</td><td>0</td><td>11 (11%)</td><td>1 (1%)</td><td>0</td><td>0</td></tr><tr><td>Muscle weakness</td><td>14 (15%)</td><td>4 (4%)</td><td>0</td><td>0</td><td>14 (14%)</td><td>4 (4%)</td><td>0</td><td>0</td></tr><tr><td>Oral mucositis</td><td>14 (15%)</td><td>1 (1%)</td><td>0</td><td>0</td><td>19 (20%)</td><td>2 (2%)</td><td>0</td><td>0</td></tr><tr><td>Vomiting</td><td>16 (17%)</td><td>4 (4%)</td><td>0</td><td>0</td><td>13 (13%)</td><td>3 (3%)</td><td>0</td><td>0</td></tr><tr><td>Dysgeusia</td><td>17 (18%)</td><td>0</td><td>0</td><td>0</td><td>17 (18%)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Hyponatremia</td><td>16 (17%)</td><td>7 (7%)</td><td>0</td><td>0</td><td>7 (7%)</td><td>4 (4%)</td><td>0</td><td>0</td></tr><tr><td>Urinary tract infection</td><td>7 (7%)</td><td>13 (14%)</td><td>0</td><td>0</td><td>6 (6%)</td><td>7 (7%)</td><td>0</td><td>0</td></tr><tr><td>Lymphopaenia</td><td>6 (6%)</td><td>11 (12%)</td><td>0</td><td>0</td><td>4 (4%)</td><td>6 (6%)</td><td>1 (1%)</td><td>0</td></tr><tr><td>Hypertension</td><td>7 (7%)</td><td>4 (4%)</td><td>0</td><td>0</td><td>5 (5%)</td><td>8 (8%)</td><td>0</td><td>0</td></tr><tr><td>Thrombocytopaenia</td><td>12 (13%)</td><td>0</td><td>0</td><td>0</td><td>10 (10%)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Sepsis</td><td>0</td><td>3 (3%)</td><td>9 (10%)</td><td>2 (2%)</td><td>0</td><td>1 (1%)</td><td>7 (7%)</td><td>0</td></tr><tr><td>Rash (maculopapular)</td><td>13 (14%)</td><td>0</td><td>0</td><td>0</td><td>8 (8%)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Febrile neutropaenia</td><td>0</td><td>9 (10%)</td><td>1 (1%)</td><td>0</td><td>2 (2%)</td><td>8 (8%)</td><td>0</td><td>0</td></tr><tr><td>Thromboembolic events</td><td>6 (6%)</td><td>3 (3%)</td><td>0</td><td>0</td><td>2 (2%)</td><td>5 (5%)</td><td>0</td><td>0</td></tr><tr><td>Intracranial haemorrhage</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td></tr><tr><td>Cardiac arrest</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td></tr><tr><td>Colonic perforation</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td></tr><tr><td>Hepatic failure</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td></tr><tr><td>Death NOS</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td></tr><tr><td>Multi-organ failure</td><td>0</td><td>0</td><td>0</td><td>1 (1%)</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></tbody></table><table-wrap-foot><p>Selected grades 1–2 (in at least 10% of patients) and grades 3, 4,
and 5 adverse events.</p><p><italic>NOS</italic> not otherwise
specified</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec14">
                <title>Exploratory analyses: serum Hsp27 levels</title>
                <p id="Par23">Of the 200 participants, 161 (80.5%) had a baseline serum Hsp27
level available (80 in arm A and 81 in arm B). Median Hsp27 level was 5.7 ng/mL.
In patients who had a baseline Hsp27 level &lt;5.7 ng/mL (<italic>n</italic> = 79), median OS was significantly higher compared to those with a
baseline level ≥5.7 ng/mL (<italic>n</italic> = 82) (median OS
9.4 vs. 4.7 months, HR: 0.51, 80% CI: 0.41–0.65, one-sided <italic>P</italic> = 0.0001, estimated 12-month OS 43.6% vs 15.2%) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Treatment with docetaxel and apatorsen improved
survival in both groups of patients with either baseline Hsp27 level &lt;5.7 ng/mL
(HR: 0.71, 80% CI: 0.50–1.00) or ≥5.7 ng/mL (HR: 0.67, 80% CI: 0.48–0.92;
two-sided <italic>P</italic> = 0.87 for interaction) compared to
docetaxel alone.<fig id="Fig3"><label>Fig. 3</label><caption><p>Kaplan–Meier estimate of overall survival (OS) according to
baseline serum Hsp27 levels. One-hundred and sixty-one patients (80.5%)
had baseline Hsp27 levels available. HR hazard ratio, CI confidence
interval</p></caption><graphic xlink:href="41416_2018_87_Fig3_HTML" id="d32e2210"/></fig></p>
                <p id="Par24">A landmark analysis was performed after cycle 2 to evaluate the
change in Hsp27 level from baseline. Eighty patients (40 in each treatment group)
had measurements available at both time points and median percentage change in
serum Hsp27 from baseline to end of cycle 2 was an increase of 20.5% (range, −76.8
to +677.8%). In patients with a decrease or ≤20.5% increase of Hsp27, treatment
with docetaxel and apatorsen significantly improved overall survival vs docetaxel
alone (HR: 0.29, 80% CI: 0.18–0.48, median OS 12.2 vs 5.1 months) compared to
those who had &gt;20.5% increase in Hsp27 levels (HR: 0.77, 80% CI: 0.46–1.30,
median OS 7.9 vs 6.8 months; two-sided <italic>P</italic> = 0.0727 for interaction).</p>
              </sec>
            </sec>
            <sec id="Sec15">
              <title>Discussion</title>
              <p id="Par25">The addition of apatorsen to docetaxel chemotherapy met its
predefined end point resulting in improved overall survival compared to docetaxel
alone in patients with metastatic urothelial carcinoma who are relapsed or
refractory after a platinum-containing regimen. Although the improvement in median
overall survival was 2 weeks, the hazard ratio and Kaplan–Meier curves show the
overall benefit for the addition of apatorsen. However, these data are hypothesis
generating and confirmatory trials are warranted to further study this targeted
agent in patients with metastatic urothelial carcinoma.</p>
              <p id="Par26">Currently in the United States, single-agent immune checkpoint
blockade with anti-PD-1/PD-L1 antibodies is the standard of care for patients
following progression on platinum-based chemotherapy,<sup><xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR24">24</xref></sup> and vinflunine is a cytotoxic
approved for this indication in the European Union.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> While the development of immune
checkpoint blockade has represented a breakthrough for patients with advanced
urothelial carcinoma, the vast majority of patients fail to respond to single-agent
PD-1 or PD-L1 inhibition with response rates of 15–25%.<sup><xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>
For these patients, there are no proven life-prolonging treatments, and the outlook
remains quite bleak. Furthermore, efficacy results from phase II trials of many of
these agents, which have led to accelerated FDA approval status, remain to be
rigorously verified in the phase III setting and, in some cases, have not been
confirmed in the subsequent phase trial.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> The phase III RANGE study, which evaluated
ramucirumab plus docetaxel in platinum-refractory metastatic urothelial carcinoma,
showed a modest PFS improvement of only 1.3 months compared to docetaxel plus
placebo.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Due to its gate-keeping statistical design, the
study does not allow for formal testing of response rate unless OS benefit reaches
HR 0.75 (currently immature). There were limited number of patients receiving immune
checkpoint blockade prior and subgroup analysis did not show any benefit in patients
with visceral metastasis. Therefore, novel agents that target chemotherapy-resistant
urothelial carcinoma are still desperately needed.</p>
              <p id="Par27">Preclinical and smaller clinical data have shed light on the
rationale for activity and benefit from ASO therapy targeting Hsp27. Hsp27 is a
stress-activated, ATP-independent, cytoprotective chaperone that is upregulated in
cancer and is associated with treatment resistance. Inhibition of Hsp27 expression
in vitro and in vivo leads to increased sensitivity to cytotoxic
chemotherapies.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>
In addition, suppression of Hsp27 may lead to long-term dormancy in vivo in the
absence of chemotherapy though inhibition of angiogenesis.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> Collectively, these findings
may provide rationale for outcomes observed on this trial: while the median
difference in overall survival was small, the hazard ratio suggests a 20% reduction
in the risk of death over the course of the study associated with the combination
treatment arm.</p>
              <p id="Par28">The biology of Hsp27 and its targeting by ASO has been shown to have
challenges. Through the interplay of TNF-α and IL-10, Hsp27 is known to have
anti-inflammatory effects.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> Further, while second-generation ASOs have
modifications to allow greater nuclease resistance and increased binding affinities
than their predecessors, potential toxicities include hybridisation-dependent
toxicities—due to on- or off-target pharmacology—and hybridisation-independent
toxicities due to nonantisense effects.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> Inhibition of Hsp27 by ASOs, therefore, may
result in tumour suppression at the expense of increased inflammation. Indeed, in
our study we noted a slightly higher incidence of sepsis (15.1% vs 8.3%; <italic>n</italic> = 14 vs 8) and urinary tract infections (14% vs 7.3%;
<italic>n</italic> = 13 vs 7) in those treated with combination
therapy. These safety signals are generally consistent with those seen in the
Borealis-1 study, which evaluated platinum-based chemotherapy with or without
apatorsen (600 or 1000 mg) vs chemotherapy plus placebo in the first-line
setting.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> Toxicity was noted to be higher in the 1000 mg
apatorsen arm compared to the 600 mg arm in that study, although the primary end
point of improved OS was not met with either apatorsen dose compared to chemotherapy
alone. In the phase III AFFINITY study of men with metastatic castration-resistant
prostate cancer who progressed after docetaxel, custirsen, an ASO to clusterin,
administered with chemotherapy showed no OS benefit vs chemotherapy
alone.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>
Our study, however, met its predefined end point and the future prospect of ASOs in
urothelial carcinoma may depend on better patient selection, for example, with
accurate biomarkers.</p>
              <p id="Par29">In our subgroup analysis, patients with lower baseline serum Hsp27
levels (&lt;5.7 ng/mL) appeared to have better overall survival than those with
higher baseline levels (≥5.7 ng/mL), irrespective of treatment. Therapy with
apatorsen and docetaxel appeared to benefit both those with lower or higher Hsp27
levels, suggesting that baseline serum Hsp27 levels may act as a potential
prognostic, but not predictive, biomarker in these patients. Furthermore,
combination treatment with apatorsen and docetaxel appeared to benefit those with
either a decline or limited increase of Hsp27 level ≤20.5% (HR: 0.29, 80% CI:
0.18–0.48) more so than those with an increase of &gt;20.5% (HR: 0.77, 80% CI:
0.46–1.30) when comparing baseline and post cycle 2 levels. This finding may suggest
that dynamic changes of Hsp27 levels in patients could serve as an indicator
predicting benefit to combination treatment. Ultimately, these findings are simply
hypothesis generating and may be informative for future trial designs.</p>
              <p id="Par30">These results should be interpreted in the context of study design.
This was a randomised, controlled, comparative trial with one-sided 0.10 alpha-level
test reflecting the objective to determine if the combination provided survival
benefit relative to docetaxel alone. The rationale for this statistical design was
that the addition of apatorsen to docetaxel was not felt to potentially yield a
negative effect compared to docetaxel alone; however, this does allow for a higher
false-positive rate and there is a potential for lead time bias with the apatorsen
run-in. In the context of recent phase III results for immunotherapy agents in this
space, our findings reinforce the importance of OS as a significant end point in
well-designed later phase studies when evaluating potential practice-impacting
treatments.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> To be eligible for our trial, patients must have
received at least one prior platinum-based chemotherapy regimen, and no patient may
have received more than two regimens for metastatic disease. While the current
landscape is evolving for patients who are platinum-ineligible, and there are new
options in the platinum-refractory setting (e.g., immunotherapy), this was not part
of established treatment paradigm at the time of our study design. Therefore, the
efficacy of apatorsen in patients having received immunotherapy is not currently
assessed and granular data on subsequent lines of therapy are not available in this
analysis. Furthermore, we only analysed serum Hsp27 levels at baseline and after
cycle 2 as a potential marker of response to treatment. Evaluating the expression of
Hsp27 measured by immunohistochemistry (IHC) in tumour tissue, as well as the effect
of therapy on peripheral circulating tumour cells (CTCs), would be meaningful
additional exploratory end points and, while not available in this current report,
are planned future analyses.</p>
              <p id="Par31">In conclusion, the addition of apatorsen to docetaxel chemotherapy
met its predefined survival end point in patients with refractory metastatic
urothelial carcinoma in this phase II trial. These data are hypothesis generating
and would require further study before informing clinical practice for this targeted
therapy in metastatic urothelial carcinoma.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>Trial registration: NCT01780545</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors acknowledge the following investigators for their
participation in this study: Madelaine Sgroi (IU Health Central Indiana Cancer
Centers); Ralph Hauke (Nebraska Methodist Hospital); Arif Hussain (University of
Maryland); John Burfeind (Froedtert &amp; The Medical College of Wisconsin);
Alexander Starodub (Goshen Center for Cancer Care); Alexandra Drakaki (University of
California Los Angeles); Sergey Devitskiy (Dartmouth-Hitchcock Medical Center);
Harry Drabkin (Medical University of South Carolina); William Adler (Memorial
Medical Cancer Center, Las Cruces); David Quinn (University of Southern California);
William Fisher (IU Health Ball Memorial Hospital Cancer Center). The authors also
acknowledge Robert Dreicer, currently at University of Virginia, and Roberto Pili,
currently at Indiana University, for their contributions.</p>
              <sec id="FPar2">
                <title>Author contributions</title>
                <p id="Par34">J.E.R., N.M.H., T.K.C., M.M.R and L.W. designed this trial. J.E.R.,
N.M.H., A.A., S.G., J.P., R.A., A.B., J.H.-C., P.G., R.L., E.G., C.H., G.S., C.A.,
M.S., J.B., S.P., and T.K.C. recruited patients. M.M.R. provided statistical
leadership, L.W. implemented the statistical analysis, and T.B. oversaw data
management. A.A.L., J.E.R., N.M.H., M.M.R., L.W., and T.K.C. drafted the
manuscript. C.J. and K.A. are OncoGenex employees. All authors contributed to the
interpretation of data, reviewing the manuscript, and gave final approval to
submit for publication.</p>
              </sec>
            </ack>
            <notes notes-type="funding-information">
              <p>This study was investigator-sponsored with support from OncoGenex
Pharmaceuticals. This work was supported in part by National Cancer Institute Cancer
Center Support grant P30 CA008748. The study was designed by the three principal
investigators (J.E.R., N.M.H., and T.K.C.). The study was conducted among academic
and community sites within the Hoosier Cancer Research Network (HCRN). None of the
funders had any role in the data analysis, interpretation of results, or a role in
writing the article. The principal investigators and statisticians (L.W. and M.M.R.)
had access to raw data. The principal investigators had the final responsibility for
the decision to submit for publication.</p>
            </notes>
            <notes id="FPar4" notes-type="COI-statement">
              <title>Conflict of interest</title>
              <p id="Par36">J.E.R. reports personal fees from OncoGenex during the conduct of
the study; personal fees from Merck, BMS, Eli Lilly, AstraZeneca, EMD Serono,
Inovio, Agensys, Genentech/Roche, Seattle Genetics, Sanofi, outside the submitted
work. N.M.H. reports research support to the institution from Novartis, OncoGenex,
Mirati, Merck, Genentech, Bristol-Myers Squibb, Heat Biologics, Acerta,
AstraZeneca, and Prinicipia Biopharma; consulting support from OncoGenex,
AstraZeneca, Merck, Bristol-Myers Squibb, Genentech, Inovio, Principia Biopharma,
Champions Oncology, Health Advances, Taris Biomedical, and Seattle Genetics.
M.M.R. reports grants from Hoosier Cancer Research Network during the conduct of
the study. S.G. reports grants from BMS, Novartis, Bayer, Agensys, Merck, Pfizer,
and Celldex during the conduct of the study; personal fees from AstraZeneca,
Bristol-Myers Squibb, Bayer, Exelixis, Novartis, and Pfizer, outside the submitted
work. J.P. reports institutional research funding from OncoGenex and Hoosier
Cancer Research Network. A.B. reports research support to the institution from
Merck, Genentech, and AstraZeneca; consulting support from AstraZeneca, Merck,
Genentech, Pfizer/EMD Serono, and Cerulian Pharma. J.H.-C. reports grants and
personal fees from Genentech; non-financial support from Genentech; personal fees
from Clovis Oncology, Novartis, Merck, and Foundation Medicine, outside the
submitted work. P.G. reports consulting with Genentech, Bayer, Dendreon,
Bristol-Myers Squibb, Merck, Exelixis, AstraZeneca, Clovis Oncology, and EMD
Serono; also participated in unbranded educational program with Genentech and
Bristol-Myers Squibb. G.S. reports grants from Boehringer-Ingelheim, Bayer,
Onyx-Amgen, and Merck; consultancy fees from Pfizer, Genentech, Novartis, Argos,
Merck, Sanofi, Agensys, Clinical Care Options, Astrazeneca, Uptodate,
Biotheranostics, Exelixis, Bristol-Myers Squibb, Janssen, Amgen, and Eisai;
personal fees from NCCN (National Comprehensive Cancer Network). T.B. is a Hoosier
Cancer Research Network employee. C.J. and K.A. are OncoGenex employees. J.B.
reports research support from Novartis and Sanofi; consulting support from
OncoGenex, AstraZeneca, Merck, Bristol-Myers Squibb, Genentech, Inovio, Champions
Oncology, Seattle Genetics, and Pierre Fabre. T.K.C. reports institutional
research funding from Pfizer, Exelixis, BMS, and Novartis; advisory roles at
Pfizer, Novartis, Genentech, Merck, BMS, and Bayer. The remaining authors L.W.,
A.A., R.A., R.L., E.A.G., C.H., C.A., M.N.S., A.A.L., and S.P. declare no
competing interests.</p>
            </notes>
            <notes id="FPar400">
              <title>Availability of data and material</title>
              <p id="Par400">All data and materials are available upon request.</p>
            </notes>
            <notes id="FPar3">
              <title>Ethical approval and consent to participate</title>
              <p id="Par35">The study was approved by the institutional review boards and/or
ethics committee at every enrolling center and was conducted in accordance with
Good Clinical Practice Guidelines and the Declaration of Helsinki. The study was
reviewed every 6 months by the Data Safety Monitoring Board of the
Dana-Farber/Harvard Cancer Center.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ischia</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>So</surname>
                      <given-names>AI</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of heat shock proteins in bladder
cancer</article-title>
                  <source>Nat. Rev. Urol.</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <fpage>386</fpage>
                  <lpage>95</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrurol.2013.108</pub-id>
                  <pub-id pub-id-type="pmid">23670183</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miyata</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Hsp90 inhibitor geldanamycin and its derivatives as
novel cancer chemotherapeutic agents</article-title>
                  <source>Curr. Pharm. Des.</source>
                  <year>2005</year>
                  <volume>11</volume>
                  <fpage>1131</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.2174/1381612053507585</pub-id>
                  <pub-id pub-id-type="pmid">15853661</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Whitesell</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Geldanamycin-stimulated destabilization of mutated p53
is mediated by the proteasome in vivo</article-title>
                  <source>Oncogene</source>
                  <year>1997</year>
                  <volume>14</volume>
                  <fpage>2809</fpage>
                  <lpage>16</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.onc.1201120</pub-id>
                  <pub-id pub-id-type="pmid">9190897</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>An</surname>
                      <given-names>WG</given-names>
                    </name>
                    <name>
                      <surname>Schulte</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Neckers</surname>
                      <given-names>LM</given-names>
                    </name>
                  </person-group>
                  <article-title>The heat shock protein 90 antagonist geldanamycin
alters chaperone association with p210bcr-abl and v-src proteins before their
degradation by the proteasome</article-title>
                  <source>Cell Growth Differ.</source>
                  <year>2000</year>
                  <volume>11</volume>
                  <fpage>355</fpage>
                  <lpage>60</lpage>
                  <?supplied-pmid 10939589?>
                  <pub-id pub-id-type="pmid">10939589</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Workman</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Overview: translating Hsp90 biology into Hsp90
drugs</article-title>
                  <source>Curr. Cancer Drug Targets</source>
                  <year>2003</year>
                  <volume>3</volume>
                  <fpage>297</fpage>
                  <lpage>300</lpage>
                  <pub-id pub-id-type="doi">10.2174/1568009033481868</pub-id>
                  <pub-id pub-id-type="pmid">14529382</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bagatell</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Whitesell</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Altered Hsp90 function in cancer: a unique therapeutic
opportunity</article-title>
                  <source>Mol. Cancer Ther.</source>
                  <year>2004</year>
                  <volume>3</volume>
                  <fpage>1021</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.4161/cbt.3.10.1142</pub-id>
                  <pub-id pub-id-type="pmid">15299085</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Whitesell</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lindquist</surname>
                      <given-names>SL</given-names>
                    </name>
                  </person-group>
                  <article-title>HSP90 and the chaperoning of cancer</article-title>
                  <source>Nat. Rev. Cancer</source>
                  <year>2005</year>
                  <volume>5</volume>
                  <fpage>761</fpage>
                  <lpage>72</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrc1716</pub-id>
                  <pub-id pub-id-type="pmid">16175177</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Somji</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sens</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Garrett</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Sens</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Todd</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Heat shock protein 27 expression in human proximal
tubule cells exposed to lethal and sublethal concentrations of
CdCl2</article-title>
                  <source>Environ. Health Persspect.</source>
                  <year>1999</year>
                  <volume>107</volume>
                  <fpage>545</fpage>
                  <lpage>52</lpage>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Storm</surname>
                      <given-names>FK</given-names>
                    </name>
                    <name>
                      <surname>Mahvi</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Gilchrist</surname>
                      <given-names>KW</given-names>
                    </name>
                  </person-group>
                  <article-title>Hsp-27 has no diagnostic or prognostic significance in
prostate or bladder cancers</article-title>
                  <source>Urology</source>
                  <year>1993</year>
                  <volume>42</volume>
                  <fpage>379</fpage>
                  <lpage>82</lpage>
                  <pub-id pub-id-type="doi">10.1016/0090-4295(93)90361-D</pub-id>
                  <pub-id pub-id-type="pmid">8212437</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lebret</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Heat shock proteins HSP27, HSP60, HSP70, and HSP90:
expression in bladder carcinoma</article-title>
                  <source>Cancer</source>
                  <year>2003</year>
                  <volume>98</volume>
                  <fpage>970</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.11594</pub-id>
                  <pub-id pub-id-type="pmid">12942564</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>HSh</surname>
                      <given-names>Kassem</given-names>
                    </name>
                    <name>
                      <surname>Sangar</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Cowan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Margison</surname>
                      <given-names>GP</given-names>
                    </name>
                  </person-group>
                  <article-title>A potential role of heat shock proteins and
nicotinamide N-methyl transferase in predicting response to radiation in bladder
cancer</article-title>
                  <source>Int. J. Cancer</source>
                  <year>2002</year>
                  <volume>101</volume>
                  <fpage>454</fpage>
                  <lpage>60</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.10631</pub-id>
                  <pub-id pub-id-type="pmid">12216074</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gleave</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Chi</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Antisense targets to enhance hormone and cytotoxic
therapies in advanced prostate cancer</article-title>
                  <source>Curr. Drug Targets</source>
                  <year>2003</year>
                  <volume>4</volume>
                  <fpage>209</fpage>
                  <lpage>21</lpage>
                  <pub-id pub-id-type="doi">10.2174/1389450033491190</pub-id>
                  <pub-id pub-id-type="pmid">12643471</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jansen</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Zangemeister-Wittke</surname>
                      <given-names>U</given-names>
                    </name>
                  </person-group>
                  <article-title>Antisense therapy for cancer-the time of
truth</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2002</year>
                  <volume>3</volume>
                  <fpage>672</fpage>
                  <lpage>83</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(02)00903-8</pub-id>
                  <pub-id pub-id-type="pmid">12424069</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kamada</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hsp27 knockdown using nucleotide-based therapies
inhibit tumour growth and enhance chemotherapy in human bladder cancer
cells</article-title>
                  <source>Mol. Cancer Ther.</source>
                  <year>2007</year>
                  <volume>6</volume>
                  <fpage>299</fpage>
                  <lpage>308</lpage>
                  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0417</pub-id>
                  <pub-id pub-id-type="pmid">17218637</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hadaschik</surname>
                      <given-names>BA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intravesically administered antisense oligonucleotides
targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive
bladder cancer</article-title>
                  <source>BJU Int.</source>
                  <year>2008</year>
                  <volume>102</volume>
                  <fpage>610</fpage>
                  <lpage>6</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07669.x</pub-id>
                  <pub-id pub-id-type="pmid">18384625</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>So</surname>
                      <given-names>AI</given-names>
                    </name>
                    <name>
                      <surname>Black</surname>
                      <given-names>PC</given-names>
                    </name>
                    <name>
                      <surname>Chi</surname>
                      <given-names>KN</given-names>
                    </name>
                    <name>
                      <surname>Hurtado-Col</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gleave</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>A phase I trial of intravesical antisense
oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of
non-muscle-invasive bladder cancer</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <fpage>286</fpage>
                  <pub-id pub-id-type="doi">10.1200/jco.2012.30.5_suppl.286</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chi</surname>
                      <given-names>KN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase I dose-escalation study of apatorsen
(OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in
patients with castration-resistant prostate cancer and other advanced
cancers</article-title>
                  <source>Ann. Oncol.</source>
                  <year>2016</year>
                  <volume>27</volume>
                  <fpage>1116</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdw068</pub-id>
                  <pub-id pub-id-type="pmid">27022067</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bellmunt</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic factors in patients with advanced
transitional cell carcinoma of the urothelial tract experiencing treatment
failure with platinum-containing regimens</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2010</year>
                  <volume>28</volume>
                  <fpage>1850</fpage>
                  <lpage>5</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2009.25.4599</pub-id>
                  <pub-id pub-id-type="pmid">20231682</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sonpavde</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Time from prior chemotherapy enhances prognostic risk
grouping in the second-line setting of advanced urothelial carcinoma: a
retrospective analysis of pooled, prospective phase 2 trials</article-title>
                  <source>Eur. Urol.</source>
                  <year>2013</year>
                  <volume>63</volume>
                  <fpage>717</fpage>
                  <lpage>23</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.eururo.2012.11.042</pub-id>
                  <pub-id pub-id-type="pmid">23206856</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bellmunt</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Borealis-1: a randomised, first-line,
placebo-controlled, phase II study evaluating apatorsen and chemotherapy for
patients with advanced urothelial cancer</article-title>
                  <source>Ann. Oncol.</source>
                  <year>2017</year>
                  <volume>28</volume>
                  <fpage>2481</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdx400</pub-id>
                  <pub-id pub-id-type="pmid">28961845</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choueiri</surname>
                      <given-names>TK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Double-blind, randomised trial of docetaxel plus
vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic
urothelial cancer</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <fpage>507</fpage>
                  <lpage>12</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2011.37.7002</pub-id>
                  <pub-id pub-id-type="pmid">22184381</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>JE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Atezolizumab in patients with locally advanced and
metastatic urothelial carcinoma who have progressed following treatment with
platinum-based chemotherapy: a single-arm, multicentre, phase 2
trial</article-title>
                  <source>Lancet</source>
                  <year>2016</year>
                  <volume>387</volume>
                  <fpage>1909</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00561-4</pub-id>
                  <pub-id pub-id-type="pmid">26952546</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sharma</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Nivolumab in metastatic urothelial carcinoma after
platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2
trial</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <fpage>312</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30065-7</pub-id>
                  <pub-id pub-id-type="pmid">28131785</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bellmunt</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pembrolizumab as second-line therapy for advanced
urothelial carcinoma</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2017</year>
                  <volume>376</volume>
                  <fpage>1015</fpage>
                  <lpage>26</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1613683</pub-id>
                  <pub-id pub-id-type="pmid">28212060</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bellmunt</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase III trial of vinflunine plus best supportive
care compared with best supportive care alone after a platinum-containing
regimen in patients with advanced transitional cell carcinoma of the urothelial
tract</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <fpage>4454</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2008.20.5534</pub-id>
                  <pub-id pub-id-type="pmid">19687335</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of durvalumab in locally advanced
or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label
study</article-title>
                  <source>JAMA Oncol.</source>
                  <year>2017</year>
                  <volume>3</volume>
                  <fpage>e172411</fpage>
                  <pub-id pub-id-type="doi">10.1001/jamaoncol.2017.2411</pub-id>
                  <pub-id pub-id-type="pmid">28817753</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patel</surname>
                      <given-names>MR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Avelumab in metastatic urothelial carcinoma after
platinum failure (JAVELIN solid tumour): pooled results from two expansion
cohorts of an open-label phase 1 trial</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2018</year>
                  <volume>19</volume>
                  <fpage>51</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30900-2</pub-id>
                  <pub-id pub-id-type="pmid">29217288</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Atezolizumab versus chemotherapy in patients with
platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor
211): a multicenter, open-label, phase 3 randomised controlled
trial</article-title>
                  <source>Lancet</source>
                  <year>2018</year>
                  <volume>391</volume>
                  <fpage>748</fpage>
                  <lpage>57</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33297-X</pub-id>
                  <pub-id pub-id-type="pmid">29268948</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petrylak</surname>
                      <given-names>DP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ramucirumab plus docetaxel versus placebo plus
docetaxel in patients with locally advanced or metastatic urothelial carcinoma
after platinum-based therapy (RANGE): a randomised, double-blind, phase 3
trial</article-title>
                  <source>Lancet</source>
                  <year>2017</year>
                  <volume>390</volume>
                  <fpage>2266</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32365-6</pub-id>
                  <pub-id pub-id-type="pmid">28916371</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Straume</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Suppression of heat shock protein 27 induces long-term
dormancy in human breast cancer</article-title>
                  <source>Proc. Natl Acad. Sci. USA</source>
                  <year>2012</year>
                  <volume>109</volume>
                  <fpage>8699</fpage>
                  <lpage>704</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.1017909109</pub-id>
                  <pub-id pub-id-type="pmid">22589302</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Kodys</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Yeh</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Miller-Graziano</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Exaggerated human monocyte IL-10 concomitant to
minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is
primarily an antiinflammatory stimulus</article-title>
                  <source>J. Immunol.</source>
                  <year>2000</year>
                  <volume>165</volume>
                  <fpage>3951</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.4049/jimmunol.165.7.3951</pub-id>
                  <pub-id pub-id-type="pmid">11034403</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frazier</surname>
                      <given-names>KS</given-names>
                    </name>
                  </person-group>
                  <article-title>Antisense oligonucleotide therapies: the promise and
the challenges from a toxicologic pathologist’s perspective</article-title>
                  <source>Toxicol. Pathol.</source>
                  <year>2015</year>
                  <volume>43</volume>
                  <fpage>78</fpage>
                  <lpage>89</lpage>
                  <pub-id pub-id-type="doi">10.1177/0192623314551840</pub-id>
                  <pub-id pub-id-type="pmid">25385330</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beer</surname>
                      <given-names>TM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Custirsen (OGX-011) combined with cabazitaxel and
prednisone versus cabazitaxel and prednisone alone in patients with metastatic
castration-resistant prostate cancer previously treated with docetaxel
(AFFINITY): a randomised, open-label, international, phase 3
trial</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <fpage>1532</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30605-8</pub-id>
                  <pub-id pub-id-type="pmid">29033099</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
